Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer
SIVAKUMAR S. et al, (2021), Molecular Biomarkers and Precision Medicine for Pancreatic, Liver and Biliary Tract Cancers
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.
Royston D. et al, (2021), Hematol Oncol Clin North Am, 35, 279 - 293
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ. et al, (2021), J Clin Oncol, 39, 1129 - 1138
Care of haematology patients in an overwhelmed healthcare system.
Willan J. et al, (2021), Br J Haematol, 193, 269 - 270
CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 96 - 96
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang P. et al, (2021), Cancer Res, 81, 1667 - 1680
Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 101 - 102
Modification of escalated beacopp with dacarbazine substitution reduces toxicity while maintaining efficacy for the treatment of advanced-stage Hodgkin lymphoma
Santarsieri A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 40 - 41
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A. et al, (2021), Br J Haematol, 193, 63 - 71
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Dalle S. et al, (2021), BMC Cancer
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Dalle S. et al, (2021), BMC Cancer
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Mapperley C. et al, (2021), J Exp Med, 218
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Willenbrock F. et al, (2021), Br J Cancer, 124, 581 - 586
Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
Louka E. et al, (2021), Journal of Experimental Medicine, 218
LARP1 isoform expression in human cancer cell lines.
Schwenzer H. et al, (2021), RNA Biol, 18, 237 - 247
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma
Herrera AF. et al, (2021), CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 19, 13 - 14
A source of hope for platinum-resistant ovarian cancer?
Blagden SP. and Nicum S., (2021), Lancet, 397, 254 - 256
Tumour gene expression signature in primary melanoma predicts long-term outcomes
Garg M. et al, (2021), Nature Communications
Application of Single Cell Approaches to Study MPN biology
MEAD A., (2021), Hematology / Oncology Clinics of North America